All these data, taken together highlight the great therapeutic potential of BCP for oral mucositis; in fact it possesses a dual mechanism of action; inhibition of NF-κB and activation of PPAR-γ that amplifies its efficacy in the first phase of inflammation and later it halts, by inhibiting STAT3, the second phase of the inflammatory response. Here, STAT3 is linked to oral mucositis.